Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How can we fix the research bias from industry sponsorship?

Ruth Macklin, PhD
Policy
April 18, 2019
99 Shares
Share
Tweet
Share

Late last year the New York Times reported that Dr. José Baselga, the chief medical officer of Memorial Sloan Kettering Cancer Center, had resigned for failing to disclose his conflicts of interest at professional meetings and in scientific and medical journals. The Times report says that Dr. Baselga — who also served as physician-in-chief at the center — “had failed to disclose millions of dollars in payments from health care companies in dozens of research articles.” It appears, though, that his wrongful conduct was not the receipt of such munificent sums from the drug industry; instead, it was his failure to disclose them.

Writing about this case in a Times opinion piece, Dr. Marcia Angell, a former editor-in-chief of the New England Journal of Medicine, says “Disclosure is better than no disclosure, but it does not eliminate the conflict of interest.” I agree. The main worry about conflict of interest in research is that it tends to bias the research in favor of the company sponsoring that research; there is ample evidence for this.

Dr. Angell provides a sound argument for that concern. She explains that one-way conflicts of interest hamper research is by suppressing negative results. Researchers are not required to publish the results of research in which, say, a pharmaceutical company’s drug does not show efficacy. She writes that one review “found that 37 of 38 positive studies—that is, studies that showed that a drug was effective—were published. But 33 of 36 negative studies were either not published or published in a form that conveyed a positive outcome.”

Eliminating the negative

When industry sponsors research, it retains control of the manuscript, reporting the results and what is subsequently published. Another well-known example of the problem at hand is the manipulation of the design of a research study so that one treatment will show more positive effects than the one under comparison. “For example, the sponsor’s drug may be compared with another drug administered at a dose so low that the sponsor’s drug looks more powerful,” Angell writes. Another article about industry support of medical research notes that “two systematic reviews found that studies sponsored by industry reported significantly greater benefits and less harm than studies with other sources of funding. Similarly, there are well-known examples where industry has squelched (or attempted to squelch) study results that were unfavorable to their products.”

How do companies get away with this kind of trickery? After all, research involving human participants has to be reviewed by an Institutional Review Board (IRB), a research ethics committee usually located in the medical school or institution where the company’s research is conducted. Most IRB members are medical researchers themselves, and should have the expertise to detect such maneuvers in the protocols they review.

Authors and authenticity

Another integrity check could occur in the peer-review process when a manuscript is submitted to a journal for publication. But even then, authors may artfully suppress maneuvers designed to favor a company’s product. An equally egregious behavior is “medical ghostwriting,” in which pharmaceutical companies hire an unnamed writer who authors the paper based on company-sponsored research, giving it a favorable spin. The company also finds prominent medical researchers willing to lend their names as authors of papers—possibly people involved in some way in the research, or “key opinion leaders” in the field.

Why would any self-respecting scientist engage in such unethical practices? It’s unclear. Yet articles in the medical and bioethics literature over the years reveal how widespread this and other unethical practices are in the world of medical publishing.

And even the National Institutes of Health (NIH) may not be completely immune from questionable aspects of research collaboration. An opinion piece in the Washington Post last year argued that the agency doesn’t police its conflicts of interest well enough. That op-ed recounts a study sponsored by beer and liquor companies designed to find alcohol’s benefits but not its potential harms. When these aspects came to light, the NIH director ended the trial. But the author of the Post piece, who spent several years as a Senate investigator studying conflict-of-interest problems at the NIH, says industry ties to NIH “go back decades and are never really addressed unless the agency faces media scrutiny and demands from the public and Congress for change.”

Diminishing corporate influence

So how can we remedy the evident bias in research resulting from industry sponsorship? Such sponsorship isn’t going away. One step that IRBs in academic institutions can take is to ensure careful review of such research by members of the committee who have no ties to industry. Another — more controversial — step is one that medical journals might adopt. Instead of merely requesting disclosure of conflict of interest by authors, journals could require authors to disclose any sums of money a sponsor has paid for activities beyond the direct cost of conducting the research. If those sums exceed a certain “reasonable amount,” the journal could refuse to publish the article.

Less controversial would be an instruction to peer reviewers to ensure that the methods used in the research do not bias the conclusions in favor of the sponsor’s product. That step might require peer reviewers to request more information from authors than appears in the manuscript submitted for publication.

Whether these or other remedies are put in place, patients and the public have a right to medical treatment stemming from research results untainted by the actions of for-profit companies that engage in manipulative or dishonest practices.

Ruth Macklin is a professor, department of epidemiology and population health, Albert Einstein College of Medicine, Bronx, NY. She blogs at the Doctor’s Tablet.

Image credit: Shutterstock.com

Prev

Do not take online physician reviews at face value

April 18, 2019 Kevin 9
…
Next

A love-hate relationship with the resume-guided voice

April 18, 2019 Kevin 0
…

Tagged as: Oncology/Hematology

Post navigation

< Previous Post
Do not take online physician reviews at face value
Next Post >
A love-hate relationship with the resume-guided voice

More by Ruth Macklin, PhD

  • Is the National Institutes of Health stifling academic freedom?

    Ruth Macklin, PhD
  • The erosion of informed consent in medical research

    Ruth Macklin, PhD
  • Why a study of medical resident hours was unethical

    Ruth Macklin, PhD

Related Posts

  • Challenging gender bias in the house of medicine

    Barbara McAneny, MD
  • Why the health care industry must prioritize health equity

    George T. Mathew, MD, MBA
  • The health insurance industry is like a house of cards

    Linda Girgis, MD
  • Bias when treating supporters of President Trump

    Anonymous
  • Advocating for a sick parent by confronting physician bias

    Erin Paterson
  • A medical student’s story of racism and bias

    Akosua Y. Oppong

More in Policy

  • The realities of immigrant health care served hot from America’s melting pot

    Stella Cho
  • Healing the damaged nurse-physician dynamic

    Angel J. Mena, MD and Ali Morin, MSN, RN
  • Deaths of despair: an urgent call for a collective response to the crisis in U.S. life expectancy

    Mohammed Umer Waris, MD
  • Breaking down the barriers to effective bar-code medication administration

    Amy Dang Craft
  • The locums industry has a beef problem

    Aaron Morgenstein, MD
  • Canada’s health workers are sounding the alarm. We must act, now.

    Ivy Lynn Bourgeault, PhD
  • Most Popular

  • Past Week

    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond pizza and pens: National Doctors’ Day should be about saving lives

      James Young, MD | Physician
    • Physicians are a finite resource we need to protect

      Jack Resneck, Jr., MD | Physician
    • From clocking in to clocking out: the transition to retirement

      Debbie Moore-Black, RN | Conditions
    • How understanding cultural backgrounds can lead to better patient care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • The Titanic sinking: a metaphor for the impending collapse of medicine

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD & Shreekant Vasudhev, MD | Physician
  • Recent Posts

    • How understanding cultural backgrounds can lead to better patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • From license to loneliness: the dilemma of retired physicians

      Richard Plotzker, MD | Physician
    • Tackling the health care crisis with artificial intelligence: Combating physician and nursing shortages in the United States

      Harvey Castro, MD, MBA | Tech
    • From hope to heartbreak: a story of loss in the ICU

      Ton La, Jr., MD, JD | Conditions
    • Unlearning our habits: a journey from intelligence to wisdom

      Brian Sayers, MD | Physician
    • Lessons from an orthopedic surgery journey [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Experts Call for PBM Transparency During Senate Hearing
  • Want to Fix Medicare Pay for Primary Care Docs? How About Two Fee Schedules?
  • OTC Narcan Approval Opens New Doors in Fight Against Opioid Crisis
  • U.S. 'Flying Blind' When It Comes to Data on Substance Use in Pregnancy
  • Fear of Family Separation a Barrier to Addiction Care During Pregnancy

Meeting Coverage

  • VTE Risk in Recurrent Ovarian Cancer Increases With More Lines of Chemotherapy
  • Obesity's Impact on Uterine Cancer Risk Greater in Younger Age Groups
  • Oral Roflumilast Effective in the Treatment of Plaque Psoriasis
  • Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer
  • Cannabis Use Common in Post-Surgery Patients on Opioid Tapering
  • Most Popular

  • Past Week

    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • Beyond pizza and pens: National Doctors’ Day should be about saving lives

      James Young, MD | Physician
    • Physicians are a finite resource we need to protect

      Jack Resneck, Jr., MD | Physician
    • From clocking in to clocking out: the transition to retirement

      Debbie Moore-Black, RN | Conditions
    • How understanding cultural backgrounds can lead to better patient care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • The Titanic sinking: a metaphor for the impending collapse of medicine

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD & Shreekant Vasudhev, MD | Physician
  • Recent Posts

    • How understanding cultural backgrounds can lead to better patient care [PODCAST]

      The Podcast by KevinMD | Podcast
    • From license to loneliness: the dilemma of retired physicians

      Richard Plotzker, MD | Physician
    • Tackling the health care crisis with artificial intelligence: Combating physician and nursing shortages in the United States

      Harvey Castro, MD, MBA | Tech
    • From hope to heartbreak: a story of loss in the ICU

      Ton La, Jr., MD, JD | Conditions
    • Unlearning our habits: a journey from intelligence to wisdom

      Brian Sayers, MD | Physician
    • Lessons from an orthopedic surgery journey [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How can we fix the research bias from industry sponsorship?
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...